Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Core Insights - Acadia Pharmaceuticals Inc. released topline results from its Phase 3 COMPASS PWS trial, which evaluated the efficacy and safety of intranasal carbetocin in patients with hyperphagia in Prader-Willi syndrome (PWS) [1][3]. Company Performance - The Phase 3 trial did not show a statistically significant improvement of intranasal carbetocin over placebo on the primary endpoint, which was the change from baseline to Week 12 on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) [3]. - The safety profile of intranasal carbetocin was consistent with previous trials, showing a low rate of adverse events [4]. - Despite the trial results, Acadia is projected to generate over $1 billion in net sales from two approved products by 2025 and has a robust pipeline with eight disclosed and multiple undisclosed programs [5]. Market Reaction - Following the trial results, ACAD stock experienced a decline of 11.02%, trading at $21 during the premarket session [6].